Altogether, our data suggest that, mechanistically, TGF-β1 activates MEK/ERK1/2 signaling, which in turn phosphorylates SREBP2 and enhances expression of enzymes involved in cholesterol synthesis, including DHCR7, which positively regulates tumor-derived EV release (Fig. 3I). Here, SREBF2 is linked to neoplasm.